Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

30.17 

-0.46 -1.5%

as of Dec 05 '19

52 Week Range:

21.75 31.24


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon to jointly develop healthcare sector-related automation, robotics, and instrumentation, as well as other technologies and infrastructure. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 1.88
2.66
3.25
5.00
5.75
6.11
growth rate 41.5% 22.2% 53.9% 15.0% 6.3%
Earnings BIT 172.27
203.99
157.78
80.02
387.95
736.12
857.69
970.37
939.41
1,067.02
994.12
growth rate 18.4% -22.7% -49.3% 384.8% 89.8% 16.5% 13.1% -3.2% 13.6% -6.8%
Avg.PE 31.70
19.96
21.69
71.94
35.21
34.25
30.98
23.99
27.84
growth rate -37.0% 8.7% 231.7% -51.1% -2.7% -3.3% -22.6% 16.1%
ROA 10.30
8.90
6.50
1.30
4.50
6.00
growth rate -13.6% -27.0% -80.0% 246.2% 33.3%
ROE 25.40
26.10
18.30
4.30
14.50
17.40
growth rate 2.8% -29.9% -76.5% 237.2% 20.0%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 186.30
207.80
224.40
408.30
366.00
462.66
608.33
477.80
528.52
385.27
401.57
growth rate 11.5% 8.0% 82.0% -10.4% 26.4% 31.5% -21.5% 10.6% -27.1% 4.2%
Acct.Payable 273.62
439.63
409.99
461.07
423.10
561.88
growth rate 60.7% -6.7% 12.5% -8.2% 32.8%
Cur.Assets 626.60
1,004.60
1,144.10
1,929.20
1,934.60
2,139.66
2,913.12
3,089.47
3,122.51
2,945.32
3,483.25
growth rate 60.3% 13.9% 68.6% 0.3% 10.6% 36.2% 6.1% 1.1% -5.7% 18.3%
Total Assets 1,180.20
1,657.20
1,889.00
5,640.00
5,627.50
5,841.04
8,449.75
9,601.72
10,129.77
10,920.26
12,477.05
growth rate 40.4% 14.0% 198.6% -0.2% 3.8% 44.7% 13.6% 5.5% 7.8% 14.3%
Cash 6.40
249.40
239.60
340.60
473.30
708.78
1,079.15
1,142.50
895.01
886.52
1,033.79
growth rate 3,796.9% -3.9% 42.2% 39.0% 49.8% 52.3% 5.9% -21.7% -1.0% 16.6%
Inventory 373.10
484.50
527.90
1,030.30
998.60
946.91
1,194.06
1,431.39
1,642.93
1,629.29
1,949.36
growth rate 29.9% 9.0% 95.2% -3.1% -5.2% 26.1% 19.9% 14.8% -0.8% 19.6%
Cur.Liabilities 317.50
299.00
423.10
646.10
592.90
715.30
1,079.71
1,053.01
1,071.76
977.99
1,257.32
growth rate -5.8% 41.5% 52.7% -8.2% 20.6% 51.0% -2.5% 1.8% -8.8% 28.6%
Liabilities 699.00
1,090.80
1,195.90
3,977.50
3,750.70
3,733.83
5,786.86
6,300.33
6,401.79
7,286.30
7,780.44
growth rate 56.1% 9.6% 232.6% -5.7% -0.5% 55.0% 8.9% 1.6% 13.8% 6.8%
LT Debt 0.00
703.20
665.40
2,072.70
1,807.30
2,469.91
4,096.78
4,565.99
4,675.01
5,872.76
6,010.97
growth rate -5.4% 211.5% -12.8% 36.7% 65.9% 11.5% 2.4% 25.6% 2.4%
Equity 481.30
566.40
693.00
1,662.50
1,876.80
2,101.26
2,658.12
3,296.20
3,721.48
3,629.08
4,225.55
growth rate 17.7% 22.4% 139.9% 12.9% 12.0% 26.5% 24.0% 12.9% -2.5% 16.4%
Common Shares 254.89
213.06
213.06
332.24
326.56
119.60
119.60
119.60
119.60
119.60
119.60
growth rate -16.4% 0.0% 55.9% -1.7% -63.4% 0.0% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 129.57
102.70
82.90
-23.10
66.10
138.46
235.89
522.59
249.42
251.51
231.98
growth rate -20.7% -19.3% -100.0% 100.0% 109.5% 70.4% 121.5% -52.3% 0.8% -7.8%
Cash Dividends 34.79
80.90
27.30
0.00
0.00
70.06
156.01
221.77
216.15
218.26
278.84
growth rate 132.5% -66.3% -100.0% 122.7% 42.2% -2.5% 1.0% 27.8%
Cash From OA 74.44
88.20
104.30
220.20
507.10
592.01
978.93
742.78
553.28
841.75
737.43
growth rate 18.5% 18.3% 111.1% 130.3% 16.7% 65.4% -24.1% -25.5% 52.1% -12.4%
Sale Purchase of Stock 155.65
71.15
71.15
0.92
growth rate -54.3% 0.0% -98.7%
FCF -55.13
-30.60
0.90
60.30
341.00
453.55
743.03
220.19
303.86
590.24
505.45
growth rate 0.0% 100.0% 6,600.0% 465.5% 33.0% 63.8% -70.4% 38.0% 94.3% -14.4%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 815.60
913.20
990.70
1,795.60
2,620.90
2,741.73
3,355.38
3,934.56
4,049.83
4,318.07
4,486.72
growth rate 12.0% 8.5% 81.3% 46.0% 4.6% 22.4% 17.3% 2.9% 6.6% 3.9%
Op.Income 202.96
226.50
209.70
278.90
660.10
736.12
857.69
970.37
939.41
1,067.02
994.12
growth rate 11.6% -7.4% 33.0% 136.7% 11.5% 16.5% 13.1% -3.2% 13.6% -6.8%
IBT 172.27
204.00
157.80
80.00
387.90
497.54
589.68
690.25
712.75
695.72
725.84
growth rate 18.4% -22.7% -49.3% 384.9% 28.3% 18.5% 17.1% 3.3% -2.4% 4.3%
Net Income 121.73
148.00
115.50
50.30
256.70
345.55
470.25
532.15
545.46
662.70
596.64
growth rate 21.6% -22.0% -56.5% 410.3% 34.6% 36.1% 13.2% 2.5% 21.5% -10.0%
EPS 0.48
0.61
0.51
0.16
0.75
1.01
growth rate 27.1% -16.4% -68.6% 368.8% 34.7%
Gross Profit 664.43
741.10
731.70
827.50
1,329.60
1,417.85
1,699.21
1,931.00
1,912.29
2,152.01
2,049.56
growth rate 11.5% -1.3% 13.1% 60.7% 6.6% 19.8% 13.6% -1.0% 12.5% -4.8%
R&D 40.70
89.40
124.40
123.27
180.75
224.19
197.62
224.65
240.66
growth rate 119.7% 39.2% -0.9% 46.6% 24.0% -11.9% 13.7% 7.1%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT 266.77
221.12
231.08
311.27
293.10
growth rate -17.1% 4.5% 34.7% -5.8%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 462.84
401.57
596.72
627.67
464.28
growth rate -13.2% 48.6% 5.2% -26.0%
Acct.Payable 561.88
540.04
growth rate -2.0%
Cur.Assets 3,024.38
3,483.25
3,488.97
3,424.36
3,659.80
growth rate 15.2% 0.2% -1.9% 6.9%
Total Assets 11,779.68
12,477.05
13,387.07
13,323.78
14,036.98
growth rate 5.9% 7.3% -0.5% 5.4%
Cash 582.01
1,033.79
576.71
553.70
792.13
growth rate 77.6% -44.2% -4.0% 43.1%
Inventory 1,864.20
1,949.36
2,115.68
2,205.76
2,327.17
growth rate 4.6% 8.5% 4.3% 5.5%
Cur.Liabilities 1,086.42
1,257.32
1,215.11
1,276.46
1,394.81
growth rate 15.7% -3.4% 5.1% 9.3%
Liabilities 7,632.31
7,780.44
8,510.00
8,437.96
8,745.11
growth rate 1.9% 9.4% -0.9% 3.6%
LT Debt 6,115.86
6,010.97
6,864.16
6,018.09
6,903.58
growth rate -1.7% 14.2% -12.3% 14.7%
Equity 4,145.03
4,225.55
4,401.15
4,393.76
4,771.87
growth rate 1.9% 4.2% -0.2% 8.6%
Common Shares 119.60
119.60
119.60
119.60
119.60
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 68.67
69.49
64.92
54.35
69.22
growth rate 1.2% -6.6% -16.3% 27.4%
Cash Dividends 139.81
139.81
101.91
101.91
growth rate 0.0% -27.1% 0.0%
Cash From OA 159.56
328.68
-167.72
313.27
193.66
growth rate 106.0% -100.0% 100.0% -38.2%
FCF 90.90
259.19
-232.63
258.92
124.44
growth rate 185.2% -100.0% 100.0% -51.9%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 1,143.80
1,222.81
1,156.78
1,266.58
1,314.42
growth rate 6.9% -5.4% 9.5% 3.8%
Op.Income 266.77
221.12
231.08
311.27
293.10
growth rate -17.1% 4.5% 34.7% -5.8%
IBT 187.41
141.11
142.85
225.45
189.70
growth rate -24.7% 1.2% 57.8% -15.9%
Net Income 149.32
128.35
114.37
172.51
136.52
growth rate -14.1% -10.9% 50.8% -20.9%
EPS
growth rate
Gross Profit 525.26
518.04
528.05
597.89
606.67
growth rate -1.4% 1.9% 13.2% 1.5%
R&D 58.23
70.18
62.61
69.96
68.42
growth rate 20.5% -10.8% 11.7% -2.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (60.28)

YOY Growth Grade:

D (45.29)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 38.71 37.67 26.50
EPS / Growth 9.2% 0.80 12.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 16.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 9.2% 12.5% 12.5%
Future PE 18.30 30.06 30.06
Future EPS 1.92 2.60 2.60
Value Price
MOS %
8.70
-71.2%
19.31
-36.0%
19.31
-36.0%
MOS Price 4.35 9.66 9.66
IRT 16.27 13.98 13.98

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.